Pacira BioSciences Faces Lawsuit Over Securities Violations: Important Dates and Details
On January 16, 2025, The Gross Law Firm released a crucial notice for shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX), alerting them to significant legal actions that could impact their investments. Shareholders who acquired shares during the specific class period are encouraged to contact the firm to explore their rights, particularly regarding a class action lawsuit linked to alleged securities law violations. The class period in question runs from August 2, 2023 to August 8, 2024.
The core of the allegations revolves around a press announcement from Pacira on August 9, 2024, relating to their legal battle with eVenus over patent infringement. In this press release, it was revealed that a court ruling invalidated Pacira's U.S. Patent No. 11,033,495, deemed crucial for their product Exparel, responsible for a staggering 80% of the firm's revenue. This dramatic turn of events raises concerning questions about the validity of other patents held by Pacira, possibly leading to an influx of generic alternatives in the market and heightened legal expenses.
The market reacted swiftly to the news, with Pacira's stock plummeting by over 47%. Closing at $22.36 per share on August 8, 2024, the price dropped to a disastrous low of $11.70 per share by the next day. This steep decline has left many shareholders anxious about the future of their investments.
Time is of the essence for affected shareholders. The Gross Law Firm warns that the deadline for registering as a lead plaintiff in this class action is March 14, 2025. Interested investors are urged to not only review their purchasing history but also to register their details to stay informed throughout the legal proceedings. Once registered, shareholders will be provided with portfolio monitoring tools that will keep them updated on the case’s progress.
Joining the class action comes at no financial risk to shareholders, as there are no costs or obligations associated with participation. The Gross Law Firm stands as a prominent advocate for investors who have endured losses due to misleading practices and fraud. They emphasize the importance of holding companies accountable and ensuring transparency in corporate governance.
In the wake of such serious allegations, stakeholders must react swiftly. Contact details for The Gross Law Firm are readily available for those seeking clarity or wishing to enroll in this class action. Their team is prepared to assist and provide guidance on the next steps for shareholders navigating this complex legal landscape.
For further insights or to register, interested parties can visit the Gross Law Firm’s official website. This situation serves as a critical reminder of the volatile nature of stock investments and the imperative for investors to stay informed regarding their rights and legal options.
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
The core of the allegations revolves around a press announcement from Pacira on August 9, 2024, relating to their legal battle with eVenus over patent infringement. In this press release, it was revealed that a court ruling invalidated Pacira's U.S. Patent No. 11,033,495, deemed crucial for their product Exparel, responsible for a staggering 80% of the firm's revenue. This dramatic turn of events raises concerning questions about the validity of other patents held by Pacira, possibly leading to an influx of generic alternatives in the market and heightened legal expenses.
The market reacted swiftly to the news, with Pacira's stock plummeting by over 47%. Closing at $22.36 per share on August 8, 2024, the price dropped to a disastrous low of $11.70 per share by the next day. This steep decline has left many shareholders anxious about the future of their investments.
Time is of the essence for affected shareholders. The Gross Law Firm warns that the deadline for registering as a lead plaintiff in this class action is March 14, 2025. Interested investors are urged to not only review their purchasing history but also to register their details to stay informed throughout the legal proceedings. Once registered, shareholders will be provided with portfolio monitoring tools that will keep them updated on the case’s progress.
Joining the class action comes at no financial risk to shareholders, as there are no costs or obligations associated with participation. The Gross Law Firm stands as a prominent advocate for investors who have endured losses due to misleading practices and fraud. They emphasize the importance of holding companies accountable and ensuring transparency in corporate governance.
In the wake of such serious allegations, stakeholders must react swiftly. Contact details for The Gross Law Firm are readily available for those seeking clarity or wishing to enroll in this class action. Their team is prepared to assist and provide guidance on the next steps for shareholders navigating this complex legal landscape.
For further insights or to register, interested parties can visit the Gross Law Firm’s official website. This situation serves as a critical reminder of the volatile nature of stock investments and the imperative for investors to stay informed regarding their rights and legal options.
Key Contacts
- - The Gross Law Firm
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.